JAK2 and essential thrombocythemia: In 2006 the MPLW515L/K was reported in ET and PMF patients (44, 45) and demonstrated to be able to aberrantly activate JAK-STAT pathway through a gain-of function similar to that of JAK2, thus leading to megakaryocytic proliferation (8–10).